---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-002738"
form_type: "8-K"
ticker: "ACON"
cik: "0001635077"
company_name: "Aclarion, Inc."
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T08:11:50.448030+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclarion updates investor deck: $14.6M cash, UK payer approvals, CLARITY trial on track for interim Q2 2026

## Summary
- Cash on hand ~$14.6M as of Apr 9 2025 10-K; runway into Q3 2026; zero debt, no preferred shares, no near-term warrant overhang.
- Secured UK payer approvals: three of top four private medical insurers now cover Nociscan, representing 5.2M people.
- Pivotal CLARITY trial fully funded ($4.6M total); first patient estimated Q2 2025; interim results expected Q2 2026.
- Expanded U.S. physician referral and commercial support; CPT Category III codes 0609T/0611T in place; Nociscan list price $1,450 vs discogram $2,000-$5,000.

## SEC filing metadata
- accession: 0001683168-25-002738
- form_type: 8-K
- ticker: ACON
- cik: 0001635077
- company_name: Aclarion, Inc.
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635077/000168316825002738/0001683168-25-002738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635077/000168316825002738/aclarion_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-002738
- JSON: https://secwatch.observer/filing/0001683168-25-002738.json
- Plain text: https://secwatch.observer/filing/0001683168-25-002738.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.